Neoadjuvant treatment options for locally advanced gastric cancer are examined, presenting a retrospective evaluation of a combined viral, immunotherapy, and chemotherapy approach. Readers will find an accessible preview of study design, safety focus, and clinical relevance for preoperative strategies.
Key Takeaways
- After patients completed two cycles of neoadjuvant treatment
- Primary endpoint of the study was the postoperative pathological response rate (pCR)
- In previous clinical studies showed immunotherapy combined with targeted therapy